Author: Healio ophthalmology

UVA, riboflavin cross-linking in treatment of infectious keratitis needs more testing

NEW YORK — UVA and riboflavin cross-linking could be considered for infectious keratitis treatments for better visual outcomes, but more studies are needed, according to a speaker here. Such methods are important to consider because only about half of patients report good visual outcomes when using traditional treatment methods after a corneal infection, Penny A. Asbell, MD, MBA, FACS said at OSN New York 2013. New possibilities also are needed because of increasing multidrug resistance to antibiotics and reduced effectiveness because antibiotic and antifungal agents often do not penetrate tissue (Read more...)

PRK offers advantages over LASIK, speaker says

NEW YORK — Photorefractive keratectomy can offer results comparable to LASIK surgery without some of the risks, according to a speaker here.In both the short and long term, photorefractive keratectomy (PRK) outcomes are similar to LASIK while eliminating flap concerns and reducing the likelihood of ectasia, Christopher E. Starr, MD, FACS, said at OSN New York 2013. PRK also now results in less pain than traditionally has been associated with the procedure and is an easier, cheaper and quicker surgery to perform than LASIK.

Early experience with new cataract surgery platform: Video with Richard L. Lindstrom, MD

NEW YORK — Richard L. Lindstrom, MD, discusses his early experience with the Alcon Centurion cataract surgery platform from OSN New York 2013.”I’ve done about 50 cases with it now,” Lindstrom said of the recently announced device. “The active fluidics, … maintaining a more stable chamber, setting whatever you want for IOP is, to me, definitely an advance.”

European patent awarded for Sjögren’s syndrome drug candidate

OphthaliX recently announced that its parent company, Can-Fite BioPharma, has been granted a patent by the European Patent Office for its drug candidate CF101 for treatment of Sjögren’s syndrome in Europe until 2025.The A3 adenosine receptor agonist is a novel small molecule, orally bioavailable drug that displayed efficacy and safety during phase 2 clinical studies, according to a press release.

Rigel focuses on discoid lupus erythematosus drug, discontinues development as RA treatment

Rigel Pharmaceuticals has announced plans to focus its resources on three lead clinical programs, including a topical dermatological JAK/SYK inhibitor for discoid lupus erythematosus.The San Francisco-based company will discontinue development of fostamatinib, an oral SYK inhibitor, for treating rheumatoid arthritis or lymphoma because of insufficient efficacy findings in recent clinical trials, as well as “the competitive landscape for the agent in these indications,” according to a press release.

Alcon launches Centurion cataract surgery platform

The Centurion Vision System, a new phacoemulsification platform, will be available this year in nations in which it has received necessary regulatory approvals, Alcon announced in a press release.“By combining multiple proprietary technologies and unique innovations as part of the Centurion Vision System, we are offering surgeons the next-generation phaco platform that will enable them to optimize every step of the cataract surgery,” Stephen Speares, Alcon’s Global Head of Cataract Franchise, said in the release.

ThromboGenics, Bicycle Therapeutics enter exclusive agreement covering new approach to DME treatment

ThromboGenics has acquired exclusive rights to develop and commercialize treatments based on Bicycle Therapeutics’ bicyclic peptides that may offer the potential to improve treatment of diabetic macular edema, according to a news release. The companies will work together on preclinical development of the bicyclic peptide inhibitors as part of the collaboration and license agreement, the release said.

What you don’t know can hurt you

In a recent decision, (Township Pharmacy v. Division of Medical Assistance and Health Services) a New Jersey appellate court upheld the denial of a pharmacy owner’s application to participate in the New Jersey Medicaid program as a pharmaceutical service provider because he failed to disclose an employee’s criminal past on his application.Despite the owner’s lack of knowledge of the pharmacy technician’s criminal background when he submitted his application to be a Medicaid provider and his subsequent firing of the employee once he discovered her criminal background, the court sustained the (Read more...)

AcuFocus adds advisory leadership team members

AcuFocus, maker of the Kamra small-aperture intracorneal inlay, has added Daniel S. Durrie, MD, Richard L. Lindstrom, MD, and John A. Vukich, MD, to its advisory leadership team, according to a company news release.“We look forward to working closely with our vast team … to ensure we meet our internal R&D, commercial, clinical and regulatory objectives,” Jim Mazzo, executive chairman and CEO for AcuFocus, said in the release.

Medflow EHR software deemed compliant

The Drummond Group’s Electronic Health Records Office of the National Coordinator Authorized Certification Body program has cleared Medflow’s EHR v8.1 software, according to a news release.The certification ensures the software is compliant with criteria adopted by the Secretary of the U.S. Department of Health and Human Services, and that users will qualify for stage 1 and 2 meaningful use, the release said.

NICE confirms recommendation for Jetrea reimbursement in England, Wales

The U.K.’s National Institute for Health and Care Excellence issued a final appraisal determination for Jetrea confirming the vitreomacular traction treatment option will be recommended for reimbursement in England and Wales via the National Health Service, according to a news release.The final appraisal determination also expanded potential cases in which use of Jetrea (ocriplasmin, ThromboGenics) may be reimbursed to include patients with symptoms of early vitreomacular traction (VMT) such as metamorphopsia, the release said. The treatment is recommended for reimbursement for full-thickness macular hole up to 400 µm in diameter (Read more...)

Adjusted keratometric readings help attain predictable postoperative refractive errors

Reducing preoperative keratometric readings by −1.19 D led to highly predictable postoperative refractive errors after cataract surgery in conjunction with Descemet’s stripping automated endothelial keratoplasty, according to a study.The prospective, interventional case series included 39 patients with Fuchs’ endothelial dystrophy and cataract scheduled for phacoemulsification, IOL implantation and DSAEK.